Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CNBC's Angelica Peebles reports on news regarding CVS. Qantas hit by cyberattack, six million customers' data potentially ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

About 69,000 new cases and nearly 14,000 deaths are expected this year, according to the American Cancer Society.

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.